Knowledge Hub
Categories:
- Allergy [1]
- Antimicrobials & infection [5]
- Autoimmune [1]
- Chemical Pathology [15]
- Endocrinology [1]
- Epidemiology [3]
- Gastrointestinal [2]
- Genetics [6]
- Genitourinary [2]
- Haematology [9]
- HIV/TB [3]
- Infectious Diseases [10]
- Neurology [4]
- Obstetric and Neonatal care [4]
- Oncology [1]
- Ophthalmology [1]
- Respiratory [2]
- Serology [3]
- Virology [38]
With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:
- In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
- Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
- DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
- The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.
In summary:
- The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
- This is true for PMB conditions as well as non-PMB conditions.
- The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
- A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
- Should any patient have a valid claim rejected because we are not a DSP, we can assist.
Invitae International Referral Service
Your doctor/genetic counsellor has ordered an Invitae genetic test for you or your child through PathCare.
Diagnosis of Prosthetic Joint Infections (PJI)
Serum-biomarkers of infection such as CRP and ESR and synovial fluid leucocyte count and neutrophil percentage are useful tests to support the diagnosis of PJI. However, it is important to define the infecting micro-organism to direct antimicrobial therapy.
Oncomine Comprehensive Plis (OncoPllus) NGS for Solid Tumours
Comprehensive genomic profiling (CGP) is advancing precision oncology through the analysis of multiple relevant biomarkers in a single next-generation sequencing (NGS) test.
Respiratory Pathogen Statistics: September 2023
Influenza A, influenza B and RSV detection rates were below 5% throughout September. Human rhinovirus/enterovirus detection rates ranged from 29.6-35.5%, thus showing a slight decrease in comparison to August.
Gastro-Intestinal Pathogen Statistics
In the past, our knowledge of the epidemiology of infective diarrhoea in routine clinical practice, was incomplete because the traditional methods of microscopy and culture are insensitive and detect only a limited range of pathogens.
Pertussis (Whooping Cough)
Pertussis is a highly infectious respiratory infection caused by Bordetella pertussis. It remains endemic in all countries, despite high vaccine coverage.
Genetic testing for hereditary cardiomyopathies and arrhythmias
Hereditary cardiomyopathy and arrhythmia disorders are genetically heterogeneous meaning that within each category there are multiple disease genes, and many different pathogenic (disease-causing) variants with overlapping phenotypes.
Respiratory Pathogen Statistics: August 2023
Influenza A and B detection rates remained below 2% during August, with the influenza season officially having ended in July.
Update on SARS-CoV-2 Variants
Two SARS-COV-2 variants are currently getting coverage in the press, namely BA.2.86 and EG.5. Both are subvariants or lineages of Omicron, however, renewed interest has stemmed from the large number of mutations detected in these viruses.